2021 Fiscal Year Final Research Report
Elucidation of mechanism of benzoylphenylurea compounds in EMT of RPE cells
| Project/Area Number |
20K18383
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 56060:Ophthalmology-related
|
|---|
| Research Institution | Yamaguchi University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2022-03-31
|
| Keywords | nAMD / BPU / 網膜下線維症 / CNV / RPE細胞 |
|---|
| Outline of Final Research Achievements |
The effects of benzoylphenylurea (BPU17) on neovascular age-related macular degeneration (nAMD) were investigated in models of subretinal fibrosis induced by retinal photocoagulation in C57BL/6J mice. To administrate vitreous injections of BPU17 inhibited subretinal fibrosis in them. Similarly, in models of choroidal neovascularization (CNV) induced by retinal photocoagulation in C57BL/6J mice, BPU17 inhibited the growth of CNV in them. BPU17 showed a trend of concentration-dependent inhibitory effects. Our results suggested that the effeccts of BPU17 inhibit the disorders of visal function induced by nAMD. We investigate the reproducibility of these models to determine the effective concentration of BPU17.
|
| Free Research Field |
眼科学領域
|
| Academic Significance and Societal Importance of the Research Achievements |
滲出型加齢黄斑変性（nAMD）に対する治療方法の第一選択は抗血管内皮増殖因子（VEGF）薬であるが、nAMD晩期の網膜下線維症には治療効果を持たない。抗VEGF薬が有効な症例であっても、治療効果を維持するために反復して長期に投与することで、網膜萎縮等の障害を生じる。BPU17はnAMDに対して抗VEGF薬とは異なる薬理機序で作用すると考えられる。本研究の結果から、BPU17がnAMDによる脈絡膜新生血管および網膜下線維症に抑制的に作用する可能性が示され、新規のnAMD治療標的として期待された。今後はBPU17の分子機序を解明することで、nAMDの病態解明に寄与する可能性が期待される。
|
